U.S., Dec. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07269873) titled 'Safety and PK Study of BICX104 With or Without Bupropion Compared to Vivitrol' on Sept. 26.
Brief Summary: Naltrexone (NTX), an opioid receptor antagonist, has a longstanding history of safe and effective use for the treatment of addictive disorders. NTX is available in several forms, such as daily oral tablets (Revia(R)) and sustained release monthly injections (Vivitrol(R)). BioCorRx Pharmaceuticals is currently developing a subcutaneous implantable pellet drug product, BICX104, which contains NTX base anhydrous (997.5 mg) and can be administered via a minor surgical procedure. BICX104 is anticipated to provide plasma concentration...